Report Type: Therapy Reports
Report Category: Blood Diseases
Report Subcategory: Paroxysmal Nocturnal Hemoglobinuria
Price: 2999.00
Date: December 2021

Paroxysmal Nocturnal Hemoglobinuria: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rarely acquired, life-threatening blood disorder in which is specified by destruction of red blood cells, blood clots and impaired bone marrow function.

Top 10 Companies:
F. Hoffmann-La Roche Ltd
Novartis AG
Takeda Pharmaceutical Co Ltd
Amgen Inc
Regeneron Pharmaceuticals Inc
UCB SA
Alexion Pharmaceuticals Inc
Handok Inc
BioCryst Pharmaceuticals Inc
Omeros Corp